Literature DB >> 10047663

Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer.

J Wang1, J Olak, M K Ferguson.   

Abstract

OBJECTIVES: We sought to determine whether diffusing capacity influences operative mortality and long-term survival after resection for lung cancer.
METHODS: We retrospectively reviewed the case histories of patients who underwent major resection for lung cancer. The association between operative mortality and predicted postoperative diffusing capacity was examined. Long-term survival among operative survivors was compared between the groups with high and low predicted postoperative diffusing capacity.
RESULTS: The group comprised 410 patients with a mean age of 62.3 years. We performed 273 lobectomies, 35 bilobectomies, and 102 pneumonectomies. A total of 32 operative deaths (7.8%) were associated with low predicted postoperative diffusing capacity (P <.001). If we examine only operative survivors, there is no significant difference in survival data between patients with a predicted postoperative diffusing capacity of less than 50 and those with a predicted figure of 50 or more (stage I, 111 vs 90 months; stage II, 26 vs 32 months; stage IIIa 32 vs 26 months; log rank P >.5 for each). On the basis of the Cox proportional hazards model, predicted postoperative diffusing capacity did not have a statistically significant effect on long-term survival (estimated hazard ratio corresponding to a 20-point decrease in predicted postoperative diffusing capacity = 1. 13; 95% confidence interval: 0.92 to 1.37).
CONCLUSION: A poor diffusing capacity is associated with high operative mortality but does not adversely affect long-term survival after major lung resection among operative survivors. Improving the perioperative management of patients undergoing major lung resection may enable inclusion of more patients with reduced diffusing capacity in the candidate pool for surgery, thus maximizing survival for early-stage lung cancer.

Entities:  

Mesh:

Year:  1999        PMID: 10047663     DOI: 10.1016/s0022-5223(99)70338-7

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Diffusing capacity predicts long-term survival after lung resection for cancer.

Authors:  Mark K Ferguson; James J Dignam; Juned Siddique; Wickii T Vigneswaran; Amy D Celauro
Journal:  Eur J Cardiothorac Surg       Date:  2012-02-24       Impact factor: 4.191

2.  Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy.

Authors:  Mark F Berry; Nestor R Villamizar-Ortiz; Betty C Tong; William R Burfeind; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2010-04       Impact factor: 4.330

3.  Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer.

Authors:  Mark F Berry; Chi-Fu Jeffrey Yang; Matthew G Hartwig; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2015-05-16       Impact factor: 4.330

4.  Forced vital capacity predicts long-term survival for curative-resected NSCLC.

Authors:  Xi Guo; Hongxin Cao; Jun Xu; Jianyu Yu; Chunlong Zheng; Long Meng; Jiajun Du
Journal:  Med Oncol       Date:  2014-08-07       Impact factor: 3.064

5.  Lung function changes and complications after lobectomy for lung cancer in septuagenarians.

Authors:  Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

Review 6.  Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Authors:  Jamie E Chaft; Andreas Rimner; Walter Weder; Christopher G Azzoli; Mark G Kris; Tina Cascone
Journal:  Nat Rev Clin Oncol       Date:  2021-04-28       Impact factor: 65.011

7.  Prediction of Overall Survival of Patients with Completely Resected Non-Small Cell Lung Cancer: Analyses of Preoperative Spirometry, Preoperative Blood Tests, and Other Clinicopathological Data.

Authors:  Mengkun Shi; Cheng Zhan; Jialun Shi; Qun Wang
Journal:  Cancer Manag Res       Date:  2019-12-13       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.